Fig 1: Nrf2 transcriptionally activates PDSS2. A, The serum levels of Nrf2 detected by ELISA. B, The level of Nrf2 detected by qRT-PCR level. C, The protein level of Nrf2 detected by Western blot. D, DNA binding motif of Nrf2 predicted by JASPAR. E, The binding sites between Nrf2 and PDSS2. F and G, The luciferase activity of HCAECs. H, The DNA affinity detected by ChIP assay. n = 3. **P < 0.01, ***P < 0.001.
Fig 2: PDSS2 suppresses ox-LDL-induced ferroptosis of HCAECs. A and B, The mRNA level of PDSS2 determined by qRT-PCR. C and D, The iron content in HCAECs. E and F, The level of GSH in HCAECs. G and H, The total ROS in HCAECs. n = 3. **P < 0.01.
Fig 3: PDSS2 is decreased in AS. A, The serum level of PDSS2 determined by ELISA. B, The specificity of PDSS2 analyzed with the receiver operating characteristic curve. C, The mRNA level of PDSS2 detected by qRT-PCR. n = 3. **P < 0.01.
Fig 4: PDSS2 suppresses the atherosclerotic lesions in vivo. A, The atherosclerotic lesions determined by Oil Red O-staining assay. B, Quantification of (A). C, The atherosclerotic lesions determined by Oil Red O-staining assay. D, Quantification of (C). n = 6. **P < 0.01, ##P < 0.01.
Fig 5: PDSS2 suppresses the death of HCAECs. A and B, Cell proliferation detected by colony formation assay. C and D, Quantification of (A) and (B), respectively. E and F, Cell survival rate determined by CCK-8 assay. n = 3. **P < 0.01.
Supplier Page from Abcam for Anti-PDSS2 antibody